Merck news from FierceBiotech
NewsDiakron in-licenses program, finds partner
Diakron Pharmaceuticals has simultaneously struck a pair of deals to in-license a Phase I oral anti-coagulant therapy from Merck while signing India's Orchid Chemicals as a development partner for Read more...
Merck suspends trial enrollment
SurModics says that Merck informed the company that results reported in a recently published study comparing laser treatment and intravitreal injections of triamcinolone acetonide in patients with Read more...
Merck, Dynavax announce Heplisav results
Dynavax and Merck announced that their hepatitis B vaccine Heplisav achieved the primary endpoint in a Phase III study. In the study, 95.1 percent of subjects who received Heplisav developed Read more...
Merck puts HIV development program on hold
Canada's Ambrilia Biopharma says that Merck has placed the development program for the HIV therapy - MK-8122 - on hold as it focuses on basic science efforts to evaluate other PL-100 prodrugs and Read more...
Pharma giants to collaborate on new discovery tech
Three of the biggest pharma companies on the planet are joining forces to back an unusual venture aimed at developing "breakthrough" discovery technology that can reduce the frequency of trial Read more...
Merck, Schering-Plough end respiratory collaboration
Merck and Schering-Plough have withdrawn their NDA for a pill combining Claritin and Singulair and are breaking up their respiratory collaboration, which has been in place since 2000. The goal of the Read more...
Study projects new wave of globalization in biopharma
Don't be misguided by dated reports discounting the impact Indian and Chinese scientists are having in drug development and other key technologies, says a new study from Duke and Harvard. Looking at Read more...
Daiichi Sankyo acquires Ranbaxy in $4.6B deal
Ranbaxy's drive to become a research-based drug developer and major manufacturer has led it straight into the Read more...
DPP-4 inhibitors get spotlight at ADA meeting
Researchers are unveiling positive data at the American Diabetes Association's meeting for new DPP-4 inhibitors for diabetes. Takeda is the latest, demonstrating that its alogliptin can control blood Read more...
Merck's osteoporosis drug performs in Phase II
Merck's experimental osteoporosis drug odanacatib turned in positive results in a Phase II trial. The drug reduced measures of bone turnover (breakdown and rebuilding of bone) in women with breast Read more...
| Press ReleasesCelera Genomics Group-an Applera Corp. Business Grants License to Merck for Cancer Targets Celera Genomics Group-an Applera Corp. Business Grants License to Merck for Cancer Targets /10/2008 ALAMEDA, Calif. -- Celera, an Applera Corporation business, today announced a two year exclusive Read more... Experimental Weight-loss Drug Cuts Appetite, Burns More Energy, Study Suggests Experimental Weight-loss Drug Cuts Appetite, Burns More Energy, Study Suggests The first clinical studies of an experimental drug have revealed that obese people who take it for 12 weeks lose Read more... Merck Sells Pennsylvania Chemicals Plant Merck Sells Pennsylvania Chemicals Plant PHILADELPHIA, Jan. 1 -- PRWT Services, Inc., a minority-owned business enterprise, today announced that it has, through its wholly-owned subsidiary, Cherokee Read more... PRESS RELEASE: Idera Pharmaceuticals, and Merck Forge $400 Million Cancer Drug Deal Idera Pharmaceuticals, and Merck Forge $400 Million Cancer Drug Deal CAMBRIDGE, Mass. -- Idera Pharmaceuticals announced today that it has entered into a worldwide licensing and collaboration Read more... PRESS RELEASE: Merck Announces Voluntary Recall of Certain Lots of PEDVAXHIB and COMVAX Merck Announces Voluntary Recall of Certain Lots of PEDVAXHIB and COMVAX WHITEHOUSE STATION, N.J., Dec. 12, 2007 - Merck & Co., Inc. announced today that the Company has initiated a voluntary Read more... |
Get more Merck coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets